Recent advances in sentinel lymph node biopsy for breast cancer

Current Opinion in Oncology

Volumn 20, Issue 6, 2008, Pages 621-626

  Goyal, Amit ^a   Mansel, Robert E ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; Lymphatic mapping; Sentinel lymph node biopsy

Indexed keywords

DYE; ISOTOPE;

ADJUVANT CHEMOTHERAPY; ASPIRATION BIOPSY; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; DIAGNOSTIC PROCEDURE; INJECTION SITE; INTRAOPERATIVE PERIOD; LYMPH NODE DISSECTION; LYMPHOSCINTIGRAPHY; MICROMETASTASIS; MORBIDITY; MULTIPLE CANCER; NEEDLE BIOPSY; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REOPERATION; REVIEW; SENTINEL LYMPH NODE BIOPSY; ULTRASOUND;

ANTINEOPLASTIC AGENTS; BIOPSY; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; FEMALE; HUMANS; MEDICAL ONCOLOGY; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASMS; QUALITY OF LIFE; RADIONUCLIDE IMAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SENTINEL LYMPH NODE BIOPSY;

EID: 55749114055     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32831369cb     Document Type: Review

References (58)

1. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2:335-339.
2. Giuliano AE, Kirgan DM, Guenther JM, Morton DL Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220:391-398.
3. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276:1818-1822.
4. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymphnode resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007; 8:881-888. The technical results of the NSAB B-32 trial (5611 women) revealed a SLN identification rate of 97.2% and a false-negative rate of 9.8%. Prior excisional biopsy significantly increased the false-negative rate.
5. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006; 98:599-609.
6. Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005; 23:4312-4321.
7. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349:546-553.
8. Zavagno G, De Salvo GL, Scalco G, et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 2008; 247:207-213. GIVOM trial has a small sample size (749 patients) but confirms that SLN biopsy is an effective and a well tolerated procedure.
9. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006; 106:4-16.
10. Cody HS III. Sentinel lymph node biopsy for breast cancer: does anybody not need one? Ann Surg Oncol 2003; 10:1131-1132.
11. Specht MC, Fey JV, Borgen PI, Cody HS III. Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy? J Am Coll Surg 2005; 200:10-14.
12. Cody HS III, Fey J, Akhurst T, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol 2001; 8:13-19.
13. Goyal A, Newcombe RG, Chhabra A, Mansel RE. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer - results of the ALMANAC validation phase. Breast Cancer Res Treat 2006; 99:203-208.
14. Hung WK, Chan CM, Ying M, et al. Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer. Br J Surg 2005; 92:1494-1497.
15. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23:7703-7720.
16. Derossis AM, Fey J, Yeung H, et al. A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg 2001; 193:473-478.
17. Klimberg VS, Rubio IT, Henry R, et al. Subareolar versus peritumoral injection for location of the sentinel lymph node. Ann Surg 1999; 229: 860-864.
18. McMasters KM, Wong SL, Martin RC, et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg 2001; 233:676-
19. 19 Povoski SP, Olsen JO, Young DC, et al. Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol 2006; 13:1412-1421.
20. Estourgie SH, Tanis PJ, Nieweg OE, et al. Should the hunt for internal mammary chain sentinel nodes begin? An evaluation of 150 breast cancer patients. Ann Surg Oncol 2003; 10:935-941.
21. van der Ent FW, Kengen RA, van der Pol HA, et al. Halsted revisited: internal mammary sentinel lymph node biopsy in breast cancer. Ann Surg 2001; 234:79-84.
22. Goyal A, Newcombe RG, Mansel RE. Clinical relevance of internal mammary node drainage in sentinel node biopsy for breast cancer. J Clin Oncol 2005; 23 (16S):519.
23. Veronesi U, Marubini E, Mariani L, et al. The dissection of internal mammary nodes does not improve the survival of breast cancer patients, 30-year results of a randomised trial. Eur J Cancer 1999; 35:1320-1325.
24. Goyal A, Newcombe RG, Mansel RE, et al. Role of routine preoperative lymphoscintigraphy in sentinel node biopsy for breast cancer. Eur J Cancer 2005;41:238-243.
25. Port ER, Fey J, Gemignani ML, et al. Reoperative sentinel lymph node biopsy: a new option for patients with primary or locally recurrent breast carcinoma. J Am Coll Surg 2002; 195:167-172.
26. Port ER, Garcia-Etienne CA, Park J, et al. Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence. Ann Surg Oncol 2007; 14:2209-2214. In this study, reoperative SLN biopsy was performed in 117 patients with local recurrence after breast conservation and either SLN biopsy or ALND. The SLN was identified in 55% patients.
27. Tew K, Irwig L, Matthews A, et al. Meta-analysis of sentinel node imprint cytology in breast cancer. Br J Surg 2005; 92:1068-1080.
28. Johnston EI, Beach RA, Waldrop SM, et al. Rapid intraoperative immunohistochemical evaluation of sentinel lymph nodes for metastatic breast carcinoma. Appl Immunohistochem Mol Morphol 2006; 14:57-62.
29. Viale G, Bosari S, Mazzarol G, et al. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 1999; 85:2433-2438.
30. Viale G, Dell'Orto P, Biasi MO, et al. Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription- polymerase chain reaction assay for mammaglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients. Ann Surg 2008; 247:136-142. The GeneSearch assay was compared with exhaustive serial frozen sectioning practiced by the European Institute of Oncology in Milan and was found to have an equivalent sensitivity to serial frozen sections taken every 1.5-2 mm.
31. Blumencranz P, Whitworth PW, Deck K, et al. Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. Am J Surg 2007; 194:426-432. This prospective multicentre validation study of 416 patients showed that the GeneSearch assay had a sensitivity of 87.6% and a specificity of 94.2%.
32. Mansel RE, Goyal A, Douglas-Jones A, et al. Detection of breast cancer metastasis in sentinel lymph nodes using intra-operative real time GeneSearch™ BLN Assay in the operating room: results of the Cardiff study. Breast Cancer Res Treat 2008. doi: 10.1007/s10549-008-0155-6. [Epub ahead of print] The Cardiff study showed that GeneSearch assay can be performed rapidly in around 30 min. The overall concordance with histology was 93.9% with sensitivity of 88.9% and specificity of 94.6%.
33. Goyal A, Douglas-Jones A, Newcombe RG, Mansel RE. Predictors of nonsentinel lymph node metastasis in breast cancer patients. Eur J Cancer 2004; 40:1731-1737.
34. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003; 10:1140-1151.
35. Park J, Fey JV, Naik AM, et al. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg 2007; 245:462-468.
36. Goyal A, Mansel RE. Sentinel lymph node biopsy in early stage breast cancer. In: Mansel R, Fodstad O, Jiang WG, editors. Metastasis of breast cancer. Netherlands: Springer; 2007. pp. 333-353.
37. Mansel RE, Goyal A. European studies on breast lymphatic mapping. Semin Oncol 2004; 31:304-310.
38. Ross MI. Sentinel node dissection in early-stage breast cancer: ongoing prospective randomized trials in the USA. Ann Surg Oncol 2001; 8:77S-81S.
39. Cox CE, Kiluk JV, Riker Al, et al. Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg 2008;206: 261-268. In this study additional positive non-SLNs were identified in 15.5% of N1mi patients and 9.3% of NO(i+) patients undergoing completion ALND. Using these data the authors argue that patients with N1mi or N0(i+) disease should be offered a complete ALND.
40. Cserni G, Gregori D, Merletti F, et al. Meta-analysis of nonsentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg 2004; 91:1245-1252.
41. van Rijk MC, Peterse JL, Nieweg OE, et al. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes. Cancer 2006;107:467-471.
42. Cowher MS, Erb KM, Poller W, Julian TB. Correlation of the use of axillary ultrasound and lymph node needle biopsy with surgical lymph node pathology in patients with invasive breast cancer. Am J Surg 2008. doi: 10.1016/j.amjsurg.2007.11.015. [Epub ahead of print] This study showed that preoperative axillary ultrasound with or without biopsy has a low sensitivity (54%) but nevertheless is useful in identifying a small subset of node-positive patients who can be spared SLN biopsy.
43. van Rijk MC, Deurloo EE, Nieweg OE, et al. Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy. Ann Surg Oncol 2006; 13:31-35.
44. Goyal A, Newcombe RG, Mansel RE, et al. Sentinel lymph node biopsy in patients with multifocal breast cancer. Eur J Surg Oncol 2004; 30:475-479.
45. Knauer M, Konstantiniuk P, Haid A, et al. Mutticentric breast cancer: a new indication for sentinel node biopsy - a multiinstitutional validation study. J Clin Oncol 2006; 24:3374-3380.
46. Schrenk P, Wayand W. Sentinel-node biopsy in axillary lymph-node staging for patients with multicentric breast cancer. Lancet 2001; 357:122.
47. The UK NHS Breast Screening Programme 2005/6 statistics, http://www.cancerscreening.nhs.uk/breastscreen. Accessibility verified 6 June 2008.
48. Goyal A, Douglas-Jones A, Monypenny I, et al. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ? Analysis of 587 cases. Breast Cancer Res Treat 2006; 98:311-314.
49. Xing Y, Foy M, Cox DD, et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 2006; 93:539-546.
50. Cox CE, Furman BT, Kiluk JV, et al. Use of reoperative sentinel lymph node biopsy in breast cancer patients. J Am Coll Surg 2008; 207:57-61. Fifty-six patients with previous SLN biopsy underwent second SLN biopsy. SLN was successfully identified in 80.4% patients. This study further adds to the existing evidence that remapping is feasible in patients with prior SLN biopsy.
51. Intra M, Trifiro G, Galimberti V, et al. Second axillary sentinel node biopsy for ipsilateral breast tumour recurrence. Br J Surg 2007; 94:1216-1219. In this study, SLN was successfully identified in 97% of patients at reoperation. The authors noted a high percentage of extraaxillaty sentinel nodes for repeat axillary operations (7.9%).
52. Taback B, Nguyen P, Hansen N, et al. Sentinel lymph node biopsy for local recurrence of breast cancer after breast-conserving therapy. Ann Surg Oncol 2006; 13:1099-1104.
53. Julian TB, Krag D, Brown A, et al. Preliminary technical results of NSARP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. Breast Cancer Res Treatment 2004; 88:S11-S12.
54. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer - a multicenter validation study. N Engl J Med 1998; 339:941-946.
55. Goyal A, Newcombe RG, Mansel RE. Clinical relevance of multiple sentinel nodes in patients with breast cancer. Br J Surg 2005; 92:438-442.
56. McCarter MD, Yeung H, Fey J, et al. The breast cancer patient with multiple sentinel nodes: when to stop? J Am Coll Surg 2001; 192:692-697.
57. van der Ploeg, I, Nieweg OE, van Rijk MC, et al. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol 2008. doi: 10.1016/j.ejso.2008.01.034. [Epub ahead of print] This meta-analysis of 48 studies (14959 patients) showed that the axillary recurrence rate in sentinel node-negative patients is 0.3% at a median followup of 34 months.
58. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347:567-575.